Abstract:
A method of treating glioblastoma in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and/or activity of P-selectin.
Abstract:
Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes.
Abstract:
Polymeric conjugates comprising a polymeric matrix having associated therewith an agent that down-regulates an activity or expression of a polypeptide associated with onset or progression of melanoma, and optionally and preferably, an additional agent that acts in synergy with said agent, are provided. Synthetic methodologies for preparing these conjugates and uses thereof in treating melanoma and other cancerous diseases are also provided.
Abstract:
The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.
Abstract:
The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.
Abstract:
A method of treating brain-metastasized cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and/or activity of P-selectin and an immunomodulatory agent. Methods of treating additional cancers are also disclosed.
Abstract:
Polymers useful for associating therewith oligonucleotides and for delivering the oligonucleotides into a cell, conjugates comprising these polymers and an oligonucleotide associated therewith, and compositions comprising same are provided. Also provided are uses of these conjugates in, for example, gene therapy, and particularly gene silencing. The disclosed polymers feature a PGA backbone, and amine-terminated pendant groups attached to at least 40% of the backbone units, and optionally further comprise alkyl pendant groups and/or other nitrogen-containing pendant groups attached to other one or more portions of the backbone units. The disclosed polymers can be cross-linked or can form a part of a block-copolymer.
Abstract:
Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed.Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.
Abstract:
A polymeric nanoparticle is disclosed which comprises: (i) at least one SARS-CoV-2 derived antigen which is capable of producing a T-cell and/or B cell response: and (ii) an antigen presenting cell targeting moiety which is attached to the outer surface of the nanoparticle. Use of the nanoparticle for treating COVID-19 is also disclosed.
Abstract:
A three dimensional (3D) model of a glioblastoma tumor made of a synthetic material and a plurality of cell types, including malignant cells and non-malignant cells of the tumor. Methods of forming the 3D tumor model are also provided, as well as systems in which the 3D tumor model can be perfused and fluidly connected to a medium containing immune cells and/or other cells and factors present in the tumor's microenvironment. Methods utilizing the 3D tumor model or the system in, for example, personalized therapy, are also provided.